Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of 14C-guadecitabine in AML, MDS, or solid tumors
NL-OMON46860Phase 1Not yet recruiting
- Sponsor
- Astex Pharmaceuticals
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guadecitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Nonhematologic neoplasms, sponsored by Astex Pharmaceuticals. Primary endpoints: Cumulative excretion and mass balance of 14C-radiolabeled drug material and Major routes of elimination and excretion. Planned start Jul 2016; status: not yet recruiting.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON46860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46860.